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AbstrAct
Objectives In an acute heart failure (AHF) setting, 
proenkephalin A 119–159 (penKid) has emerged as a 
promising prognostic marker for predicting worsening 
renal function (WRF), while bioactive adrenomedullin 
(bio-ADM) has been proposed as a potential marker for 
congestion. We examined the diagnostic value of bio-
ADM in congestion and penKid in WRF and investigated 
the prognostic value of bio-ADM and penKid regarding 
mortality, rehospitalisation and length of hospital stay in 
two separate European AHF cohorts.
Methods Bio-ADM and penKid were measured in 530 
subjects hospitalised for AHF in two cohorts: Swedish 
HeArt and bRain failure inVESTigation trial (HARVEST-
Malmö) (n=322, 30.1% female; mean age 75.1+11.1 
years; 12 months follow-up) and Italian GREAT Network 
Rome study (n=208, 54.8% female; mean age 78.5+9.9 
years; no follow-up available).
Results PenKid was associated with WRF (area under 
the curve (AUC) 0.65, p<0.001). In multivariable logistic 
regression analysis of the pooled cohort, penKid showed 
an independent association with WRF (adjusted OR (aOR) 
1.74, p=0.004). Bio-ADM was associated with peripheral 
oedema (AUC 0.71, p<0.001), which proved to be 
independent after adjustment (aOR 2.30, p<0.001). PenKid 
was predictive of in-hospital mortality (OR 2.24, p<0.001). 
In HARVEST-Malmö, both penKid and bio-ADM were 
predictive of 1-year mortality (aOR 1.34, p=0.038 and aOR 
1.39, p=0.030). Furthermore, bio-ADM was associated 
with rehospitalisation (aOR 1.25, p=0.007) and length of 
hospital stay (β=0.702, p=0.005).
Conclusion In two different European AHF cohorts, bio-
ADM and penKid perform as suitable biomarkers for early 
detection of congestion severity and WRF occurrence, 
respectively, and are associated with pertinent clinical 
outcomes.
IntROduCtIOn
The cardiorenal syndrome can generally be 
defined as a pathophysiological disorder of 
the heart and kidneys, where acute or chronic 
dysfunction in one organ may induce acute or 
chronic dysfunction in the other organ.1 Wors-
ening renal function (WRF) and neurohor-
monal activation are important contributors 
to fluid retention and acute decompensa-
tion in heart failure. The use of biomarkers 
might help to differentiate between different 
phenotypes in acute heart failure (AHF) with 
different outcomes and optimal treatment 
strategies. Biomarkers reflecting haemod-
ynamic stress/systolic dysfunction are the 
B-type natriuretic peptides (BNP/N-ter-
minal proBNP (NT-proBNP)), which are 
often used to follow the progression of heart 
failure.2 However, their prognostic value in 
predicting death in AHF is suboptimal.3 Also, 
high baseline values of BNP in patients with 
AHF have not shown any association with 
clinical signs of congestion,4 5 and NT-proB-
NP-guided therapy was recently shown not to 
Key questions
What is already known about this subject?
 ► In an acute heart failure setting, proenkephalin 
A 119–159 (penKid) has emerged as a promising 
prognostic marker for predicting worsening renal 
function with much faster reactivity time then creat-
inine, while bioactive adrenomedullin (bio-ADM) has 
been proposed as a potential marker for assessment 
of residual congestion.
What does this study add?
 ► This study substantiates the scarce knowledge 
about both bio-ADM and penkid and identifies two 
novel biomarkers for congestion assessment and 
kidney function. Congestion assessed by bio-ADM 
was associated with longer hospital stay and higher 
risk of rehospitalisation. penkid was associated with 
worsening renal function and higher risk of both 
in-hospital and postdischarge mortality.
How might this impact on clinical practice?
 ► Bio-ADM might help identify subjects with residual 
congestion, who could benefit from intensified di-
uretic therapy. penKid, with its fast rise when kid-
neys are damaged, could help identify patients who 
do not tolerate the intensified diuretic therapy, faster 
than creatinine.
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significantly improve time to first hospitalisation or cardi-
ovascular mortality.6
A biomarker reflecting renal status, Cystatin C, has been 
found to predict clinical outcomes in patients with AHF 
with greater accuracy than creatinine, estimated glomer-
ular filtration rate (eGFR) and blood urea nitrogen. 
However, these results derive mostly from patients with 
apparently preserved renal function and may not be 
applicable to patients with heart failure with concomitant 
renal dysfunction.3 Consequently, new biomarkers are 
called on for an improved cardiorenal risk stratification 
of patients with AHF.
Bioactive adrenomedullin (bio-ADM) is a vasoactive 
peptide hormone and a protective factor of vascular 
integrity.7 A new immunoassay especially developed 
to measure bio-ADM8 was recently used in a study 
suggesting bio-ADM as a marker of congestion in AHF.9 
Furthermore, bio-ADM has been shown to be associated 
with adverse events within 30 days after hospitalisation for 
AHF.10
Enkephalin peptides exert cardiodepressive effects.11 
One of those is proenkephalin A 119–159 (penKid, also 
described as PENK), freely filtered through the glomer-
ulus.12 In chronic heart failure, higher penKid concen-
trations were found to be associated with lower GFR and 
renal blood flow.13 PenKid has also been shown to predict 
adverse clinical outcomes in acute myocardial infarc-
tion14 and AHF.15 Thus, the possibility to adequately assess 
congestion together with real time renal function could 
be of significant value in the prediction and prevention 
of the cardiorenal syndrome and ultimately improving 
patient care.
In the present study, taking advantage of two sepa-
rate AHF cohorts from Sweden and Italy, we examined 
the association between bio-ADM and clinical signs of 
congestion and the relationship between penKid and 
WRF. Furthermore, we assessed the possible impact of 
bio-ADM and penKid related to worsening of prognosis 
for each biomarker separately.
MetHOds
HARVest-Malmö
The HeArt and bRain failure inVESTigation trial 
(HARVEST-Malmö)16 is an ongoing study in Malmö, 
Sweden, with the sole inclusion criteria being admitted 
to a cardiology or internal medicine ward for treatment 
of heart failure regardless of the aetiology, duration or 
severity. Between March 2014 and August 2018, 324 
consecutive patients admitted to cardiology or internal 
medicine wards under the diagnosis of either new onset 
or worsening chronic congestive heart failure were 
enrolled. Inability to consent to the study was the only 
exclusion criteria. For patients with severe cognitive 
impairment, defined as mini mental test examination 
score <13 points, the relatives are instead being informed 
and asked for permission for the patient’s behalf. The 
study was complied with the Declaration of Helsinki. A 
written informed consent was obtained from all partici-
pants.
GReAt network Rome
Between May 2013 and March 2015, 245 patients that 
were referred to the emergency department of Sant’An-
drea hospital complaining of heart failure symptoms and 
signs and who received a final diagnosis of new onset or 
worsening chronic congestive heart failure were enrolled 
to the GREAT Network Acute Heart Failure Rome Study, 
with inability to consent to the study as the only exclu-
sion criteria. The study protocol was complied with the 
Declaration of Helsinki. A written informed consent was 
obtained from all participants.
Clinical examination
In both cohorts, the examination included a clinical 
examination, blood sample donations and blood pres-
sure measurements at admission. Diabetes was defined as 
either self-reported physician diagnosis of type 1 or type 
2 diabetes, or use of antidiabetic medication or fasting 
plasma glucose ≥7 mmol/L. Prior heart failure was 
defined as either prior hospitalisation for heart failure or 
a heart failure diagnosis prior to inclusion in the study.
Laboratory assays
All laboratory assays are described in the online Supple-
mental Material.
Outcomes
In both cohorts, patients were examined for signs of 
congestion (dyspnoea, oedema, signs of congestion on 
X-ray and auscultatory lung rales). Further, a clinical 
congestion score (CCS) was calculated by summing the 
individual scores for each sign of congestion. A score 
from 0 to 4 points was attributed to each patient.
WRF was defined as an increase of plasma creatinine 
of >26.5 μmol/L or 0.3 mg/dL or 50% higher than the 
admission value within 48 hours of admission.15 17 In-hos-
pital mortality was defined as all-cause mortality during 
the hospital stay in both cohorts. For HARVEST-Malmö, 
where we had follow-up data, 1-year mortality was defined 
as all-cause mortality within 1 year from study inclusion 
and obtained from Swedish total population register 
Statistics Sweden.
Rehospitalisation (available in HARVEST-Malmö only) 
was defined as the first of any unplanned readmissions for 
worsening heart failure until 2 July 2018 and was obtained 
through regional administrative patient registries.
statistics
In both cohorts, variables with non-normal distribution 
(bio-ADM and penKid) were log-transformed and normal-
ised (using z-score transformation) prior to analyses. 
Since different assays were used for natriuretic peptides, 
the data from both cohorts were log transformed and 
then normalised (using z-score transformation) prior to 
pooling of the natriuretic peptide data. For all analyses, 
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Table 1 Baseline characteristics of the HARVEST-Malmö cohort, the GREAT Network Rome cohort and the pooled cohort
HARVEST-Malmö 
N=322
GREAT Network Rome 
N=208 Pooled cohort N=530 P value
Demographics 
  Age (years) 75.1±11.1 78.5±9.9 76.4±10.7 <0.001
  Female sex (%) 97 (30.1) 114 (54.8) 211 (39.8) <0.001
  Smoking (%) 38 (11.8) 29 (13.9) 67 (12.6) 0.450
Clinical profile, n (%) 
  Systolic blood pressure (mm Hg) 137.3±27.5 150.7±33.7 142.3±30.8 <0.001
  Diastolic blood pressure (mm Hg) 73.6±12.6 81.4±16.8 77.0±14.9 <0.001
  Ejection fraction (%) 38 (24–52) 40 (27–50) 40 (25–50) 0.036
Medical history, n (%) 
  Diabetes mellitus 119 (37.0) 75 (36.1) 194 (36.6) 0.720
  Prior heart failure 200 (62.1) 85 (40.9) 285 (53.8) <0.001
  Prevalent atrial fibrillation 153 (47.5) 96 (46.2) 249 (47.0) 0.762
Medication, n (%) 
  ACE inhibitors/ARB 251 (77.9) 109 (52.4) 360 (67.9) <0.001
  Beta-blockers 279 (86.6) 101 (48.6) 380 (71.7) <0.001
  Diuretics 306 (95.0) 132 (63.5) 438 (82.6) <0.001
Laboratory 
  Bio-ADM (pg/mL) 39.6 (25.6–64.5) 24.6 (9.5–48.4) 34.6 (18.7–59.3) <0.001
  penKid (pmol/L) 85.3 (62.8–118.4) 109.5 (81.7–168.5) 91.8 (67.9–135.9) <0.001
  BNP (pg/mL) – 756 (366–1452) – –
  NT-proBNP (pg/mL) 4096 (2212–8645) 7811 (2038–10851) – –
  Creatinine (mg/dL) admission 1.32±0.64 1.44±0.91 1.37±0.76 0.069
  Creatinine (mg/dL) after 48 hours 1.35±0.64 1.53±1.0 1.42±0.81 0.016
  Potassium (mmol/L) 3.8±0.5 4.3±0.6 4.0±0.6 <0.001
  Sodium (mmol/L) 140.5±3.3 137.3±5.9 139.2±4.7 <0.001
  Haemoglobin (g/L) 127.6±18.3 123.2±24.8 125.9±21.2 0.019
Outcomes 
  Peripheral oedema (n (%)) 215 (58.0) 145 (59.2) 338 (63.4) 0.004
  WRF (n (%)) 30 (8.1) 37 (20.7) 67 (14.3) <0.001
  In-hospital mortality (n (%)) 7 (1.9) 17 (8.2) 24 (5.1) <0.001
  1-year mortality (n (%)) 50 (17.2) – – –
  Rehospitalisation (n (%)) 188 (66.2) – – –
  Length of hospital stay (days) 7 (4–9) 6 (3–8) 6 (4–9) 0.320
Continuous data presented as mean±SD or median (Q1–Q3), depending on distribution.
ARB, angiotensin receptor blocker; BNP, B-type natriuretic peptide;CXR, chest X-ray;HARVEST, HeArt and bRain failure inVESTigation trial; NT-
proBNP, N-terminal proBNP; bio-ADM, bioactive adrenomedullin; penKid, proenkephalin A 119–159.
subjects with missing data on any of the covariates were 
excluded.
The area under the curve (AUC) of bio-ADM for 
peripheral oedema, in-hospital mortality, 1-year mortality 
and rehospitalisation was calculated by receiver oper-
ating characteristic (ROC) analysis. As for penKid, AUC 
was calculated for WRF and in-hospital mortality. The 
cross-sectional associations of bio-ADM with each of the 
four signs of congestion, as well as bio-ADM with CCS, 
were explored using logistic regression models.
Correlations between penKid and creatinine on admis-
sion were explored using Spearman’s correlation test. 
The cross-sectional associations of penKid and WRF 
were explored using two logistic regression models: 
crude (univariable) and in the pooled cohort adjusted 
for diabetes, systolic blood pressure (SBP), ACE inhib-
itor (ACEi), angiotensin receptor blockers (ARB), beta-
blockers, prior heart failure, creatinine and BNP, all 
previously associated with WRF (multivariable). The 
cross-sectional associations of bio-ADM and penKid with 
in-hospital mortality were explored using univariable and 
bivariable logistic regression models due to the low event 
rate (24 events in the pooled cohort).
In HARVEST-Malmö, additional analyses were 
carried out for 1-year mortality and rehospitalisation at 
follow-up, using Cox regression models. In analyses of 
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rehospitalisation, subjects that deceased during hospital 
stay were excluded from the model prior to analysis. 
Analyses of length of hospital stay were obtained using 
linear regression models.
Analyses were performed using IBM SPSS Statistics 
V.25 and a two-sided p<0.05 was considered statistically 
significant.
ResuLts
Detailed characteristics of the study populations are 
presented in table 1. Number of events for peripheral 
oedema and WRF within low and high levels of bio-ADM 
and penKid are presented in the online supplementary 
table 1, where low and high levels are defined based on 
previous descriptions in literature.8 12
Congestion
The ROC analyses for bio-ADM and peripheral oedema 
resulted in an AUC of 0.745 (95% CI 0.684 to 0.807) 
(HARVEST-Malmö), 0.651 (95% CI 0.576 to 0.726) 
(GREAT Network Rome) and 0.710 (95% CI 0.663 to 
0.757) (pooled cohort). Logistic regression analyses 
carried out for bio-ADM and each sign of congestion 
(dyspnoea, oedema, signs of pulmonary oedema on chest 
X-ray and lung rales) revealed that each one SD increment 
of bio-ADM was significantly associated with peripheral 
oedema (table 2). The distribution of bio-ADM according 
to peripheral oedema for each centre is illustrated in 
figure 1. Analyses of bio-ADM and severe congestion 
(congestions score of 4) revealed significant associations 
between each one SD increment of bio-ADM and risk of 
having the highest congestion score; however, those asso-
ciations are driven mainly by the presented associations 
of bio-ADM and peripheral oedema (table 2). Subgroup 
analyses revealed that the association of bio-ADM and 
peripheral oedema was present and significant in both 
sexes when analysed separately (men: OR 2.46 (95% CI 
1.63 to 3.69); p<0.001 and women: OR 2.17 (95% CI 1.56 
to 3.03); p<0.001) in fully adjusted model.
Worsening renal function
Spearman correlation analyses for penKid and plasma 
creatinine at admission resulted in R of 0.577 (p<0.001) 
(HARVEST-Malmö), 0.645 (p<0.001) (GREAT Network 
Rome) and 0.598 (p<0.001) (pooled cohort).
The ROC analyses for penKid and WRF resulted in an 
AUC of 0.654 (95% CI 0.552 to 0.757) (HARVEST-Malmö), 
0.591 (95% CI 0.490 to 0.692) (GREAT Network Rome) 
and 0.652 (95% CI 0.583 to 0.721) (pooled cohort). In 
crude logistic regression models, and further adjusted 
for diabetes, SBP, ACEi, angiotensin receptor blockers 
(ARB), beta-blockers, prior heart failure, creatinine and 
BNP in the pooled cohort, penKid was associated with 
WRF (table 3). Further, we also analysed WRF using the 
delta creatinine (creatine after 48 hours—creatinine at 
admission) as a dependent variable in multivariate linear 
regression analyses, and the analyses revealed significant 
associations between penKid and delta creatinine (crude 
model (β −0.422; p=0.002); multivariate model adjusted 
for diabetes, SBP, ACEi, ARB, beta-blockers, prior heart 
failure, creatinine and BNP (β −0.392; p=0.004) in the 
pooled cohort. The distribution of penKid according to 
WRF for each centre is illustrated in figure 2. Subgroup 
analyses revealed that the association of penKid and 
WRF was present and significant in men (OR 3.72 (95% 
CI 2.00 to 6.92); p<0.001), but only a trend was seen in 
women (OR 1.42 (95% CI 0.98 to 2.05); p=0.063) in fully 
adjusted model.
In-hospital mortality
Bioactive adrenomedullin
Univariable and bivariable logistic regression models 
exploring associations of bio-ADM with in-hospital 
mortality are presented in table 4 (n=470; 24 events). As 
for ROC analyses, the AUC for bio-ADM and in-hospital 
mortality was 0.614 (95% CI 0.467 to 0.761) (HARVEST-
Malmö), 0.657 (95% CI 0.507 to 0.807) (GREAT Network 
Rome) and 0.606 (95% CI 0.483 to 0.729) (pooled 
cohort). Subgroup analyses revealed that the associa-
tion of bio-ADM and in-hospital mortality was present 
and significant in men (OR 1.76 (95% CI 1.04 to 2.97); 
p=0.034), but not in women (OR 1.33 (95% CI 0.69 to 
2.56); p=0.394). However, due to the low number of 
events when analysed separately, those results should be 
interpreted with caution.
Proenkephalin
Univariable and bivariable logistic regression models 
exploring associations of penKid with in-hospital 
mortality are presented in table 4, where penKid was asso-
ciated with in-hospital mortality in all analyses. The ROC 
analyses for penKid and in-hospital mortality resulted in 
an AUC of 0.630 (95% CI 0.396 to 0.864) (HARVEST), 
0.732 (95% CI 0.596 to 0.868) (GREAT Network Rome) 
and 0.735 (95% CI 0.618 to 0.851) (pooled cohort). 
Subgroup analyses revealed that the association of penKid 
and in-hospital mortality was present and significant in 
both sexes when analysed separately (women: OR 1.78 
(95% CI 1.06 to 3.00); p=0.029 and men: OR 2.71 (95% 
CI 1.59 to 4.62); p<0.001).
One-year mortality
Due to the low event rate for in-hospital mortality in 
HARVEST-Malmö, we performed additional analyses of 
biomarkers and 1-year mortality (n=290, 50 events).
Bioactive adrenomedullin
ROC analyses of bio-ADM for 1-year mortality resulted 
in an AUC of 0.586 (95% CI 0.502 to 0.669), p=0.044. 
Cox regression models revealed that each one SD incre-
ment in bio-ADM was associated with increased 1-year 
mortality in the crude model (HR 1.38, 95% CI 1.03 to 
1.74, p=0.029), age-adjusted and sex-adjusted model (HR 
1.33, 95% CI 1.03 to 1.72, p=0.029) and further adjusted 
for diabetes, SBP, atrial fibrillation, smoking, NT-proBNP 
and prior heart failure (HR 1.35, 95% CI 1.01 to 1.79, 
p=0.043).
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Figure 1 Distribution of bio-ADM according to signs of 
peripheral oedema within each centre. HARVEST-Malmö 
n=301, 215 events (p<0.001), GREAT Network Rome n=208, 
123 events (p=0.080). bio-ADM, bioactive adrenomedullin, 
HARVEST, HeArt and bRain failure inVESTigation trial.
Table 3 Associations of penKid and worsening renal function
Univariable
HARVEST-Malmö GREAT Network Rome Pooled cohort
N=323 (30 events) N=178 (37 events) N=501 (67 events)
OR 95% CI P value OR 95% CI P value OR 95% CI P value
Age 0.98 0.95 to 1.02 0.299 1.01 0.97 to 1.04 0.715 1.00 0.98 to 1.03 0.932
Sex 6.72 1.57 to 28.8 0.010 0.94 0.48 to 1.84 0.847 1.22 0.73 to 2.04 0.443
Diabetes 1.40 0.65 to 3.03 0.389 1.12 0.56 to 2.2 0.751 1.23 0.74 to 2.04 0.425
SBP 1.00 0.98 to 1.01 0.621 1.01 1.00 to 1.02 0.158 1.01 1.00 to 1.02 0.100
ACE-i 0.72 0.34 to 1.52 0.384 1.32 0.66 to 2.64 0.432 0.83 0.51 to 1.37 0.468
ARB 0.60 0.22 to 1.64 0.320 0.52 0.21 to 1.31 0.165 0.54 0.28 to 1.06 0.074
Betablockers 1.32 0.38 to 4.56 0.665 1.20 0.61 to 2.36 0.590 0.81 0.47 to 1.39 0.444
Prior HF 1.14 0.84 to 1.55 0.407 0.71 0.35 to 1.42 0.330 0.90 0.62 to 1.31 0.590
Creatinine 2.73 1.79 to 4.18 <0.001 1.16 0.83 to 1.62 0.396 1.63 1.28 to 2.08 <0.001
BNP 1.16 0.79 to 1.70 0.459 0.90 0.64 to 1.26 0.532 1.01 0.78 to 1.29 0.966
PenKid 1.81 1.21 to 2.70 0.004 1.37 0.99 to 1.89 0.059 1.67 1.31 to 2.14 <0.001
Multivariable 
Age 0.98 0.95 to 1.01 0.173
Sex 1.54 0.80 to 2.98 0.197
Diabetes 0.92 0.51 to 1.66 0.919
SBP 1.00 0.99 to 1.01 0.373
ACEi 0.80 0.43 to 1.50 0.483
ARB 0.47 0.21 to 1.04 0.063
BB 0.98 0.50 to 1.91 0.946
Prior HF 1.02 0.72 to 1.43 0.926
BNP 0.78 0.57 to 1.06 0.115
Creatinine 1.68 0.69 to 4.05 0.251
PenKid 1.74 1.20 to 2.53 0.004
Values are OR with 95% CI. Multivariable results are reported for the pooled cohort adjusted for variables known from literature.
ACE-I, ACE inhibitors; ARB, angiotensin receptor blocker; BNP, B-type natriuretic peptide;HARVEST, HeArt and bRain failure inVESTigation trial; HF, 
heart failure; SBP, systolic blood pressure; penKid, proenkephalin A 119–159.
Figure 2 Distribution of penKid according to worsening 
renal function in each centre. HARVEST-Malmö n=323, 30 
events (p=0.003), GREAT Network Rome n=178, 37 events 
(p=0.050). PenKid, proenkephalin A 119–159HARVEST, HeArt 
and bRain failure inVESTigation trial.
Proenkephalin
ROC analyses of penKid and 1-year mortality resulted in 
an AUC of 0.639 (95% CI 0.549 to 0.729), p=0.001. Cox 
regression models revealed that each one SD increment 
in penKid levels was associated with increased 1-year 
mortality in crude analyses (HR 1.66, 95% CI 1.31 to 2.10, 
p<0.001), in an age-adjusted and sex-adjusted model (HR 
1.49, 95% CI 1.14 to 1.94, p=0.004) and further adjusted 
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Table 4 Logistic regression model for in-hospital mortality for bio-ADM and penKid
Univariable Bivariable: BioADM Bivariable: PenKid
OR 95% CI P value OR 95% CI P value OR 95% CI P value
Age 1.04 0.99 to 1.09 0.067 1.54 1.03 to 2.31 0.037 2.16 1.49 to 3.13 <0.001
Sex 0.53 0.24 to 1.16 0.112 1.58 1.05 to 2.37 0.028 2.19 1.53 to 3.14 <0.001
Diabetes 0.85 0.37 to 1.92 0.689 1.52 1.01 to 2.28 0.045 2.23 1.56 to 3.19 <0.001
SBP 0.99 0.98 to 1.01 0.254 1.48 0.98 to 2.25 0.063 2.28 1.59 to 3.27 <0.001
ACE-i 0.60 0.26 to 1.36 0.217 1.49 0.99 to 2.23 0.056 2.24 1.56 to 3.21 <0.001
ARB 0.92 0.46 to 1.81 0.798 1.51 1.01 to 2.27 0.049 2.27 1.58 to 3.25 <0.001
Betablockers 0.20 0.09 to 0.46 <0.001 1.61 1.08 to 2.40 0.020 2.08 1.44 to 3.00 <0.001
Prior HF 0.54 0.25 to 1.19 0.127 1.63 1.09 to 2.46 0.018 2.22 1.56 to 3.15 <0.001
Creatinine 1.77 1.27 to 2.46 0.001 1.38 0.90 to 2.11 0.139 2.31 1.51 to 3.53 <0.001
BNP 1.28 0.85 to 1.92 0.235 1.42 0.93 to 2.15 0.105 2.29 1.56 to 3.35 <0.001
Smoking 0.43 0.10 to 1.84 0.255 1.47 0.97 to 2.21 0.067 2.25 1.57 to 3.23 <0.001
Prevalent AF 0.47 0.20 to 1.09 0.078 1.50 1.01 to 2.25 0.047 2.18 1.53 to 3.11 <0.001
Bio-ADM 1.50 1.00 to 2.26 0.051 2.19 1.52 to 3.15 <0.001
penKid 2.24 1.57 to 3.20 <0.001 1.34 0.88 to 2.03 0.168
Values are OR with 95% CI. All results are reported for the pooled cohort (n=470, 24 events). Univariable results are presented as each variable’s 
associations with in-hospital mortality. Bivariable results are reported for penKid and bio-ADM, adjusted for each variable separately.
ACE-I, ACE inhibitors; AF, atrial fibrillation; ARB, angiotensin receptor blocker; BNP, B-type natriuretic peptide; Bio-ADM, bioactive adrenomedullin; 
HF, heart failure; SBP, systolic blood pressure; penKid, proenkephalin A 119–159.
Figure 3 The clinical use of Bioactive adrenomedullin 
(bio-ADM) and proenkephalin A 119–159 (penKid) for 
management of heart failure.
for diabetes, SBP, atrial fibrillation, smoking, NT-proBNP 
and prior heart failure (HR 1.35, 95% CI 1.04 to 1.77, 
p=0.027).
Rehospitalisation
Bioactive adrenomedullin
ROC analyses of bio-ADM and rehospitalisation resulted 
in AUC of 0.585 (95% CI 0.517 to 0.654), p=0.017. Anal-
yses of bio-ADM and risk of rehospitalisation (n=284; 188 
events; mean follow-up time 174 days) were carried out in 
a crude model (HR 1.19, 95% CI 1.05 to 1.36, p=0.008), 
age-adjusted and sex-adjusted model (HR 1.19, 95% CI 
1.05 to 1.36, p=0.008) and further adjusted for diabetes, 
SBP, atrial fibrillation, smoking, log-transformed and 
z-normalised BNP and prior heart failure (HR 1.15, 95% 
CI 1.06 to 1.47, p=0.007) and revealed that each one SD 
increment of bio-ADM was associated with increased risk 
of rehospitalisation.
Proenkephalin
Analyses of penKid and risk of rehospitalisation revealed 
that there were no significant associations (data not 
shown).
Length of hospital stay
Bioactive adrenomedullin
In linear regression analyses in the pooled cohort, each 
one SD increment of bio-ADM was associated with longer 
hospital stay on admission in crude analysis (β 0.700; 
p=0.004), in age-adjusted and sex-adjusted analysis (β 
0.709; p=0.003), and remained so after further adjust-
ment for diabetes, SBP, prevalent atrial fibrillation, 
smoking and prior heart failure (β 0.702; p=0.005).
Proenkephalin
In linear regression analyses, no significant associations 
were seen for penKid and length of hospital stay (data 
not shown).
dIsCussIOn
In this observational study of two AHF cohorts, we 
could show that bio-ADM was a suitable biomarker for 
early detection and quantification of congestion severity 
(mainly driven by peripheral oedema), risk of rehospital-
isation and longer hospital stay, while penKid was a suit-
able biomarker in detection of WRF occurrence and both 
in-hospital and 1-year mortality. This is, to our knowledge, 
the first time that data regarding penKid and bio-ADM 
are presented when used simultaneously in patients with 
AHF in two independent cohorts. These data imply that  on
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in an everyday clinical setting, bio-ADM and penKid 
could be useful to guide diuretic therapy. Since increased 
bio-ADM is associated with clinical congestion, this might 
be used to identify individuals with the need of intensified 
diuretic therapy. As treatment of AHF and decongestion 
might be harmful to the kidneys, the combination of the 
two biomarkers appears advantageous, where penKid can 
aid in guiding the treatment so not to jeopardise renal 
function (figure 3).
Bioactive adrenomedullin
Bio-ADM is known as a vasodilation factor,18 and the 
prognostic value of bio-ADM has been shown in several 
different critical conditions.8 19 20 Moreover, its predictive 
role was recently extended to the AHF setting. Self et al 
showed that in patients with AHF, higher bio-ADM levels 
were associated with the composite primary outcome 
consisting of death, rehospitalisation, emergency dial-
ysis, cardiac arrest with resuscitation, respiratory failure, 
prolonged hospitalisation and acute coronary syndrome 
within 30 days.10 Furthermore, they suggested that 
bio-ADM provides predictive information independent 
of more established biomarkers in AHF such as natriu-
retic peptides and troponins. This view is supported by 
our findings where bio-ADM predicted 1-year mortality 
and in-hospital mortality. The confirmation of conges-
tion by laboratory results is, at present, challenging, and 
the evaluation of bio-ADM might provide a new opportu-
nity to guide clinical decisions. In this context, our find-
ings showing high levels of bio-ADM to be associated with 
increased length of hospital stay and increased risk of 
rehospitalisation are of great interest, suggesting bio-ADM 
as a possible new tool to pinpoint which patients could 
benefit from a more active treatment in order to reduce 
length of stay and risk of readmission. This reasoning is 
further supported by a recent study by Kremer et al9 that 
showed a significant decrease in bio-ADM for admitted 
patients with AHF with little or no residual congestion 
after 1 week, compared with patients with significant 
residual congestion. Further, bio-ADM was the strongest 
predictor of prevalent congestion among 13 covariates.9 
Recently, a promising drug candidate (adrecizumab) 
targeting bio-ADM has been developed.21 22
Proenkephalin
PenKid is considered an inflammation-independent 
marker of kidney function that allows the early diagnosis 
of acute kidney injury by predicting the future change 
in serum creatinine.23 Its highly dynamic nature enables 
close monitoring of renal function. In our study, penKid 
correlated with serum creatinine levels. In addition, 
penKid was associated with WRF and both in-hospital and 
1-year mortality. These results are in line with Ng et al’s 
study in the AHF setting,15 as well as in the stable heart 
failure setting.24
The pathophysiological mechanism suggested for 
penKid, both in WRF and its prognostic value in 
mortality, might be related to cardiodepressive effects 
of enkephalins11 which would cause reduced kidney 
perfusion and advancing heart failure. This theory is 
supported by the results from the Acute Decompensated 
Heart Failure National Registry where administration of 
opiates resulted in worse prognosis in heart failure.25
Even if bio-ADM and penKid most likely reflect different 
pathophysiological mechanisms (ie, bio-ADM and 
congestion, penKid and WRF), the combination of the 
two could yield complementary information regarding 
the cardiorenal syndrome in patients with AHF. Further 
prospective studies are indeed warranted.
study limitations
An important strength of the current study is the use of 
two well-characterised prospective AHF cohorts. There 
are, however, several limitations with this study. The two 
cohorts, while fairly comparable in age and have a medical 
history, differ significantly in use of medications as well as 
mortality rate with a lower event rate in the HARVEST 
cohort. This is most likely due to the fact that patients 
in the HARVEST cohort were recruited from the wards, 
while the patients in the GREAT Network Rome cohort 
were recruited directly from the emergency depart-
ment. Consequently, treatment for AHF (ie, diuretics) 
was already initiated in most patients in the HARVEST 
cohort. The low-event rate is also most likely an effect of 
this as the most severe cases of AHF with the worst prog-
nosis would be treated in the intensive care unit or the 
cardiac intensive care unit and not in one of the partic-
ipating recruiting wards in the HARVEST cohort. The 
aetiology of heart failure was not registered. Data on 
signs of congestion, which was the basis for our conges-
tion score, were not collected per protocol prospectively, 
but gathered retrospectively from the admittance record 
and thus subjected to the admitting doctor’s precision 
and record-keeping. This could explain the lack of signif-
icance for the congestive signs other than peripheral 
oedema, as they presumably are more subjective and 
more prone to include conditions other than congestion. 
Data on congestion at discharge was not available, and 
we acknowledge that assessment of residual congestion 
at discharge would have added value to the study, espe-
cially paired with serial measurements of bio-ADM and 
penKid. Finally, the study was undertaken in individuals 
of mainly European descent, and the conclusions may 
not be generalisable to all ancestries.
COnCLusIOn
In two separate AHF cohorts, bio-ADM and penKid 
perform as suitable biomarkers for early detection of 
congestion severity and WRF occurrence, respectively, 
and are both associated with adverse clinical outcomes. 
The simultaneous evaluation of the two biomarkers in 
patients with AHF could provide important information in 
therapeutic decision-making in order to reduce patient’s 
mortality, in-hospital length of stay and rehospitalisation 
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rate. Further prospective studies are needed to confirm 
this hypothesis.
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